Cargando…

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma

Blockade of the programmed cell death 1-programmed cell death ligand 1 pathway is a new and promising therapeutic approach in Hodgkin lymphoma (HL). To our knowledge, the impact of soluble programmed cell death ligand 1 (sPD-L1) serum levels on HL patient prognosis has not yet been investigated. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Xiaofang, Wang, Juan, Jin, Jietian, Chen, Hao, Zhen, Zijun, Jiang, Wenqi, Lin, Tongyu, Huang, Huiqiang, Xia, Zhongjun, Sun, Xiaofei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2018
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058012/ https://www.ncbi.nlm.nih.gov/pubmed/29698935 http://dx.doi.org/10.1016/j.tranon.2018.03.012

Ejemplares similares

Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors
por: Huang, JiaJia, et al.
Publicado: (2010)

Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy
por: Wang, Hua, et al.
Publicado: (2015)

High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients
por: Wang, Hua, et al.
Publicado: (2016)

High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma
por: Lu, Tianzhu, et al.
Publicado: (2020)

Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma
por: Cai, Qingqing, et al.
Publicado: (2014)

Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy
por: Jin, Jianjun, et al.
Publicado: (2018)

Soluble CD40 ligand inhibits the growth of non-Hodgkin's lymphoma cells through the JNK signaling pathway
por: Feng, Zhongxin, et al.
Publicado: (2021)

Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin's lymphoma patients
por: Silva, Bárbara de Oliveira, et al.
Publicado: (2022)

Serum soluble toll-like receptor 2 and 4 as diagnostic and prognostic biomarkers for non-Hodgkin lymphoma
por: Fakhry, Nouran, et al.
Publicado: (2020)

DNA content and prognosis of non-Hodgkin's lymphoma.
por: Morgan, D. R., et al.
Publicado: (1986)

The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy
por: Cai, Qingqing, et al.
Publicado: (2016)

The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis
por: Zhao, Shu, et al.
Publicado: (2018)

Lactate Dehydrogenase 5 Expression in Non-Hodgkin Lymphoma Is Associated with the Induced Hypoxia Regulated Protein and Poor Prognosis
por: Lu, Renquan, et al.
Publicado: (2013)

TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis
por: Xu, Peipei, et al.
Publicado: (2017)

Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease.
por: Pizzolo, G., et al.
Publicado: (1987)

Identification of Predictive Pathways for Non-Hodgkin Lymphoma Prognosis
por: Han, Xuesong, et al.
Publicado: (2010)

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T‐cell lymphomas
por: Zhang, Xuhan, et al.
Publicado: (2019)

Elevated circulating myeloid‐derived suppressor cells associated with poor prognosis in B‐cell non‐Hodgkin's lymphoma patients
por: Wang, Yangyang, et al.
Publicado: (2022)

Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma
por: Li, Yang, et al.
Publicado: (2021)

Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
por: Gu, Xiaobin, et al.
Publicado: (2016)

Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance
por: Fisher, Kevin E., et al.
Publicado: (2022)

Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis.
por: Akerman, M., et al.
Publicado: (1987)

HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
por: Jacobson, Caron A., et al.
Publicado: (2012)

Genetic Variation in Cell Death Genes and Risk of Non-Hodgkin Lymphoma
por: Schuetz, Johanna M., et al.
Publicado: (2012)

Assessing Prognostic Factors in Hodgkin's Lymphoma: Multistate Illness-Death Model
por: Javanmardi, Fatemeh, et al.
Publicado: (2018)

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
por: Cho, Inju, et al.
Publicado: (2020)

Association between extranodal natural killer/T-cell lymphoma and hepatitis B viral infection: a case-control study
por: Wang, Kefeng, et al.
Publicado: (2017)

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2014)

Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer
por: Sun, Jin, et al.
Publicado: (2020)

Peripheral T Cell Non-Hodgkin's Lymphoma following Treatment of Hodgkin's Lymphoma
por: Chang, Sun Hee, et al.
Publicado: (2015)

High plasma soluble thrombomodulin levels indicated poor prognosis of decompensated liver cirrhosis: a prospective cohort study
por: Wei, Xinhuan, et al.
Publicado: (2022)

Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma
por: Pazgal, I, et al.
Publicado: (2002)

Immunogenic Cell Death (ICD)-Related Gene Signature Could Predict the Prognosis of Patients with Diffuse Large B-Cell Lymphoma
por: Ping, Liqin, et al.
Publicado: (2022)

Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
por: Rehn, S., et al.
Publicado: (1995)

Non-Hodgkin's Lymphomas
por: Proctor, S.J.
Publicado: (1994)

EBV in Hodgkin Lymphoma
por: Massini, Giuseppina, et al.
Publicado: (2009)

Pathobiology of Hodgkin Lymphoma
por: Piccaluga, Pier Paolo, et al.
Publicado: (2011)

Pathobiology of Hodgkin Lymphoma
por: Agostinelli, Claudio, et al.
Publicado: (2014)

Cutaneous Hodgkin's lymphoma
por: Ambekar, Asawari Anant, et al.
Publicado: (2017)

Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
por: Zhong, Jian-Hong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6rkj9ffpv6eq558ufu4mpidatr